Bank of America’s Cytosorbents Corp CTSO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $22.1K | Buy |
39,123
+417
| +1% | +$285 | ﹤0.01% | 5649 |
|
|
2025
Q4 | $24.7K | Buy |
38,706
+3
| +0% | +$2 | ﹤0.01% | 6007 |
|
|
2025
Q3 | $36.1K | Sell |
38,703
-371
| -0.9% | -$365 | ﹤0.01% | 6929 |
|
|
2025
Q2 | $50K | Sell |
39,074
-4,905
| -11% | -$4.92K | ﹤0.01% | 6812 |
|
|
2025
Q1 | $44K | Buy |
43,979
+9,528
| +28% | +$10K | ﹤0.01% | 6781 |
|
|
2024
Q4 | $31.4K | Buy |
34,451
+8
| +0% | +$8 | ﹤0.01% | 6747 |
|
|
2024
Q3 | $51.7K | Sell |
34,443
-8
| -0% | -$9 | ﹤0.01% | 6528 |
|
|
2024
Q2 | $24.2K | Sell |
34,451
-2,447
| -7% | -$2.12K | ﹤0.01% | 6693 |
|
|
2024
Q1 | $35.1K | Sell |
36,898
-29,882
| -45% | -$29.1K | ﹤0.01% | 6615 |
|
|
2023
Q4 | $74.1K | Sell |
66,780
-1,134
| -2% | -$1.68K | ﹤0.01% | 6487 |
|
|
2023
Q3 | $128K | Buy |
67,914
+290
| +0.4% | +$832 | ﹤0.01% | 6136 |
|
|
2023
Q2 | $243K | Sell |
67,624
-1,542
| -2% | -$4.88K | ﹤0.01% | 5713 |
|
|
2023
Q1 | $233K | Sell |
69,166
-4,654
| -6% | -$14K | ﹤0.01% | 5837 |
|
|
2022
Q4 | $114K | Sell |
73,820
-7,660
| -9% | -$11.4K | ﹤0.01% | 6179 |
|
|
2022
Q3 | $111K | Sell |
81,480
-29,758
| -27% | -$58.1K | ﹤0.01% | 6292 |
|
|
2022
Q2 | $244K | Buy |
111,238
+68,652
| +161% | +$158K | ﹤0.01% | 5945 |
|
|
2022
Q1 | $136K | Sell |
42,586
-17,678
| -29% | -$63.3K | ﹤0.01% | 6697 |
|
|
2021
Q4 | $252K | Buy |
60,264
+32
| +0.1% | +$180 | ﹤0.01% | 6354 |
|
|
2021
Q3 | $489K | Sell |
60,232
-992
| -2% | -$8.06K | ﹤0.01% | 5657 |
|
|
2021
Q2 | $462K | Sell |
61,224
-25,085
| -29% | -$211K | ﹤0.01% | 5494 |
|
|
2021
Q1 | $750K | Buy |
86,309
+12,544
| +17% | +$120K | ﹤0.01% | 5059 |
|
|
2020
Q4 | $588K | Buy |
73,765
+10,831
| +17% | +$90.6K | ﹤0.01% | 4898 |
|
|
2020
Q3 | $502K | Sell |
62,934
-2,499
| -4% | -$22.5K | ﹤0.01% | 4713 |
|
|
2020
Q2 | $648K | Buy |
65,433
+7,360
| +13% | +$67.6K | ﹤0.01% | 4429 |
|
|
2020
Q1 | $449K | Buy |
58,073
+1,604
| +3% | +$8.1K | ﹤0.01% | 4576 |
|
|
2019
Q4 | $217K | Sell |
56,469
-3,700
| -6% | -$16.1K | ﹤0.01% | 5587 |
|
|
2019
Q3 | $303K | Sell |
60,169
-17,218
| -22% | -$100K | ﹤0.01% | 5406 |
|
|
2019
Q2 | $511K | Buy |
77,387
+8,539
| +12% | +$58.7K | ﹤0.01% | 5053 |
|
|
2019
Q1 | $521K | Sell |
68,848
-14,641
| -18% | -$114K | ﹤0.01% | 4987 |
|
|
2018
Q4 | $675K | Buy |
83,489
+46,840
| +128% | +$465K | ﹤0.01% | 4721 |
|
|
2018
Q3 | $473K | Buy |
36,649
+2,052
| +6% | +$25.7K | ﹤0.01% | 4990 |
|
|
2018
Q2 | $395K | Buy |
34,597
+3,134
| +10% | +$29.7K | ﹤0.01% | 5027 |
|
|
2018
Q1 | $222K | Buy |
31,463
+26,463
| +529% | +$200K | ﹤0.01% | 5318 |
|
|
2017
Q4 | $33K | Buy |
+5,000
| New | +$31.8K | ﹤0.01% | 6237 |
|
|
2017
Q3 | – | Sell |
-200
| Closed | -$1K | – | 7080 |
|
|
2017
Q2 | $1K | Buy |
200
+155
| +344% | +$680 | ﹤0.01% | 6803 |
|
|
2017
Q1 | $0 | Buy |
+45
| New | +$251 | ﹤0.01% | 7005 |
|
|
2016
Q3 | – | Sell |
-6,540
| Closed | -$29K | – | 7136 |
|
|
2016
Q2 | $29K | Buy |
+6,540
| New | +$28.5K | ﹤0.01% | 6090 |
|
|
2015
Q3 | – | Sell |
-97
| Closed | -$1K | – | 7240 |
|
|
2015
Q2 | $1K | Buy |
+97
| New | +$660 | ﹤0.01% | 7117 |
|
|
2015
Q1 | – | Sell |
-800
| Closed | -$8K | – | 7138 |
|
|
2014
Q4 | $8K | Buy |
+800
| New | +$7.83K | ﹤0.01% | 7128 |
|
Other funds holding CTSO
AC
VCM
SC
CM
SIG
VFT
Bank of America's CTSO Position: Q1 2026 in Review
Bank of America increased its Cytosorbents Corp (CTSO) stake by 1.1% in Q1 2026, buying an estimated $285 and bringing the position to 39,123 shares worth $22.1K. The position accounts for ﹤0.01% of the portfolio, ranked #5649.
Bank of America first reported a position in CTSO in Q4 2014 and has held it in 39 quarters since. The position peaked at $750K in Q1 2021. 50 funds tracked by Wall St. Rank hold CTSO as of Q1 2026.
- Bank of America held 39,123 shares of Cytosorbents Corp worth $22.1K as of Q1 2026.
- Bank of America bought 417 Cytosorbents Corp shares in Q1 2026, an estimated $285.
- Cytosorbents Corp made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5649 holding.
- Bank of America first reported a position in Cytosorbents Corp in Q4 2014 and has held it in 39 quarters since.
- Bank of America's Cytosorbents Corp position peaked at $750K in Q1 2021.
- 50 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.